

PSMA617-TCMC TFA

Chemical Properties


CAS No. : 2937423-47-5

Formula: C₆₅H₈₆F₁₂N₁₄O₂₁S

Molecular Weight: 1659.52

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	PSMA617-TCMC is a derivative of PSMA-617 with structure modification, in which the carboxy groups in DOTA ring is replaced by TCMC macrocycle. PSMA-617 is a ligand used to make ¹⁷⁷ Lu-PSMA-617, which is a radioactive molecule to fight cancer.
Targets(IC50)	Others

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.6026 mL	3.0129 mL	6.0258 mL
5 mM	0.1205 mL	0.6026 mL	1.2052 mL
10 mM	0.0603 mL	0.3013 mL	0.6026 mL
50 mM	0.0121 mL	0.0603 mL	0.1205 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, Gaertner FC, Awang ZH, Hauser S, Essler M. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy. *Oncotarget*. 2017 Oct 7;8(61):103108-103116. doi: 10.18632/oncotarget.21600. eCollection 2017 Nov 28. PubMed PMID: 29262549; PubMed Central PMCID: PMC5732715.
- von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K, Joensuu T. Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. *Eur J Nucl Med Mol Imaging*. 2017 Dec 16. doi: 10.1007/s00259-017-3895-x. [Epub ahead of print] Review. PubMed PMID: 29247284.
- Rahbar K, Ahmadzadehfar H, Boegemann M. (177)Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial? *Eur J Nucl Med Mol Imaging*. 2017 Nov 21. doi: 10.1007/s00259-017-3892-0. [Epub ahead of print] PubMed PMID: 29164300.
- Eppard E, de la Fuente A, Benešová M, Khawar A, Bundschuh RA, Gärtner FC, Kreppel B, Kopka K, Essler M, Rösch F. Clinical Translation and First In-Human Use of [(44)Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. *Theranostics*. 2017 Sep 26;7(18):4359-4369. doi: 10.7150/thno.20586. eCollection 2017. PubMed PMID: 29158832; PubMed Central PMCID: PMC5695136.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481